Biotricity reports Q1 EPS (3c) vs (49c) last year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Should l Buy ?
Financial Performance: Biotricity reported a Q1 revenue of $3.9M, up from $3.2M in Q4, achieving positive EBITDA and marking a significant milestone in transitioning from a loss-making startup to a profitable business.
Technological Advancements and Partnerships: The company is enhancing its Cardiac AI Cloud platform through strategic partnerships, aiming for FDA clearance for its AI clinical model, and targeting access to 90% of U.S. hospitals to improve cardiac care solutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
